ConductScience.org, home

Comparison · NCT01986114-43545f94

SM-13496 20-120mg (Overall, 28 Weeks) vs SM-13496 20-120mg (Japan, 52 Weeks): Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. SM-13496 20-120mg (Overall, 28 Weeks) vs SM-13496 20-120mg (Japan, 52 Weeks): Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder. Trial comparisons, record NCT01986114-43545f94. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01986114-43545f94

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02830.01690.0469wilson
Risk in group 20.09050.0580.138wilson
Risk difference, group 1 minus group 2-0.0622-0.111-0.0247newcombe hybrid score
Risk ratio, group 1 over group 20.3130.1590.616log
Odds ratio, group 1 over group 20.2930.1430.601log
Number needed to treat, for one fewer participant with the outcome on SM-13496 20-120mg (Overall, 28 Weeks) than on SM-13496 20-120mg (Japan, 52 Weeks)16.18.9740.4from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1SM-13496 20-120mg (Overall, 28 Weeks)once daily orally~SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 28 weeks14495OG000
Group 2SM-13496 20-120mg (Japan, 52 Weeks)once daily orally~SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 52 weeks18199OG001

Outcome

Type
SECONDARY
Title
Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.
Description
The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.
Time frame
Baseline to 52 weeks
Population

Source ClinicalTrials.gov

Trial

Title
A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
NCT number
NCT01986114
Phases
PHASE3
Conditions
Bipolar I Disorder
Interventions
SM-13496
Lead sponsor
Sumitomo Pharma Co., Ltd.
Results first posted
2019-07-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01986114-43545f94